Q&A on the investigational vaccine candidate M72/AS01E

1. What is the M72/AS01E vaccine candidate? M72/AS01E is a subunit vaccine comprised of an immunogenic fusion protein (M72) derived from two Mycobacterium tuberculosis (M.tb) antigens (MTB32A and MTB39A), and the GlaxoSmithKline (GSK) proprietary adjuvant AS01E. AS01E is the same adjuvant used in Shingrix GSK vaccine, as well as in the new malaria vaccine RTS,S/AS01E.
2. Who developed and who manufactured the vaccine? The M72/AS01E vaccine candidate is being developed by the pharmaceutical company GlaxoSmithKline, in partnership with AERAS. AERAS is a not for profit organization based in the US, aimed at supporting tuberculosis vaccine research, funded by the Bill and Melinda Gates foundation, the UK Department for International Development (DFID), and other organizations.
3. What is…